SCHEMBL829754

SCHEMBL829754

Cc1ccc2cc(OC(=O)N3CCCc4ccccc43)ccc2n1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 9/20 0.48
TSHR P16473 4/20 0.48
HPGD P15428 3/20 0.48
LMNA P02545 2/20 0.48
NOTUM Q6P988 1/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830354 0.93 LMNA (0.52) SMN1; SMN2TDP1ALDH1A1TSHRLMNA
SCHEMBL7601844 0.80 ALDH1A1 (0.66) SMN1; SMN2ALDH1A1TSHRHPGDLMNA
SCHEMBL829224 0.79 ACHE (0.48) SMN1; SMN2ALDH1A1TSHRHPGDNOTUM
SCHEMBL828658 0.78 SMN1; SMN2 (0.65) SMN1; SMN2TDP1ALDH1A1TSHRLMNA
SCHEMBL829646 0.77 SMN1; SMN2 (0.68) SMN1; SMN2TDP1ALDH1A1TSHRHPGD
SCHEMBL830461 0.76 SMN1; SMN2 (0.51) SMN1; SMN2TDP1ALDH1A1TSHRHPGD
SCHEMBL7217123 0.75 KMT2A (0.65) SMN1; SMN2ALDH1A1TSHRHPGDLMNA
SCHEMBL833986 0.73 FAAH (0.54) SMN1; SMN2ALDH1A1TSHRLMNAMAPT
SCHEMBL830239 0.73 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1TSHRHPGDLMNA
SCHEMBL5426108 0.72 NOTUM (0.65) SMN1; SMN2ALDH1A1TSHRHPGDNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 SMN1; SMN2 4842/4885TDP1 4085/4885ALDH1A1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.